<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4717">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01705002</url>
  </required_header>
  <id_info>
    <org_study_id>PROMITIL-01</org_study_id>
    <nct_id>NCT01705002</nct_id>
  </id_info>
  <brief_title>Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.</brief_title>
  <official_title>A Phase I, Dose-Escalating, Safety Study of an Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer Patients With Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lipomedix Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lipomedix Pharmaceuticals Inc.</source>
  <oversight_info>
    <authority>Israel: Ministry of Health, Pharmaceutical department</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, double-center, Dose-Escalating, Safety Study of an Intravenously
      Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in
      Cancer Patients with Solid Tumors. The study comprised of eight cohorts, with three subjects
      per cohort. Eligible subjects will be assigned, successively in order of accrual, to one of
      eight cohorts, to receive escalating doses of intravenously infused PROMITIL. PROMITIL will
      be administered as an intravenous infusion. Dose escalation will only proceed in the absence
      of dose-limiting toxicity (DLT). For this purpose, each cohort will only begin its first
      cycle of PROMITIL when the cohort preceding it has successfully completed its first 4-week
      cycle without any signs of DLT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximal Tolerated Dose (MTD) of PROMITIL</measure>
    <time_frame>First cycle of treatment (4 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Only DLTs occurring during the first cycle of treatment for each participant will determine MTD endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT) of PROMITIL</measure>
    <time_frame>First cycle of treatment (4 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile of PROMITIL</measure>
    <time_frame>3 cycles of treatment (12 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>PK assessments will monitor plasma levels of MLP and metabolite (MMC), as well as PK parameters (Cmax, AUC0-t, AUC 0-∞, MRT, t½ , Kel, Cl, VD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor responses to the delivered PROMITIL regimens</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile of PROMITIL</measure>
    <time_frame>3 cycles of treatment (12 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Cancer</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Cohort A: Promitil 0.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatment cycles, intravenous infusion of Promitil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Promitil 1.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatment cycles, intravenous infusion of Promitil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: Promitil 1.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatment cycles, intravenous infusion of Promitil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D: Promitil 2.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatment cycles, intravenous infusion of Promitil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E: Promitil 2.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatment cycles, intravenous infusion of Promitil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort F: Promitil 3.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatment cycles, intravenous infusion of Promitil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort G: Promitil 3.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatment cycles, intravenous infusion of Promitil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort H: Promitil 4.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatment cycles, intravenous infusion of Promitil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Promitil</intervention_name>
    <arm_group_label>Cohort A: Promitil 0.5 mg/kg</arm_group_label>
    <arm_group_label>Cohort B: Promitil 1.0 mg/kg</arm_group_label>
    <arm_group_label>Cohort C: Promitil 1.5 mg/kg</arm_group_label>
    <arm_group_label>Cohort D: Promitil 2.0 mg/kg</arm_group_label>
    <arm_group_label>Cohort E: Promitil 2.5 mg/kg</arm_group_label>
    <arm_group_label>Cohort F: Promitil 3.0 mg/kg</arm_group_label>
    <arm_group_label>Cohort G: Promitil 3.5 mg/kg</arm_group_label>
    <arm_group_label>Cohort H: Promitil 4.0 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients diagnosed with inoperable, recurrent or metastatic malignant solid tumors,
             deemed incurable, and who have either:

               -  Failed to respond to standard therapy or

               -  For whom no standard therapy is available or

               -  Refuse to receive standard therapies

          2. Histologically or cytologically confirmed diagnosis of solid tumor on file.

          3. Age 18-80 years

          4. BMI: 18-36

          5. ECOG Performance Status ≤ 2

          6. Estimated life expectancy of at least 3 months

          7. Adequate bone marrow function (an absolute neutrophil count ≥1500/mm3, hemoglobin
             ≥9.5 g/dl, HgbA1C≤7%, and a platelet count ≥100,000/mm3(

          8. Adequate liver function (serum bilirubin ≤2.0 mg/100 ml; alanine aminotransferase ≤2×
             ULN)

          9. Adequate renal function (serum creatinine ≤1.5 mg/100 ml or creatinine clearance ≥45
             ml/min/1.73m2)

         10. No prior intravenous treatment with Mitomycin-C either alone or in combination

         11. No other myelosuppressive treatment within 4 weeks before start of the study drug.

         12. No other anti-cancer treatment within 2 weeks before start of  the study drug

         13. No prior extensive radiotherapy (e.g., whole pelvis total neuroaxis or greater than
             50% of neuroaxis, whole abdomen, whole body or half-body) or bone marrow
             transplantation with high dose chemotherapy and/or total body irradiation.

         14. Women of child bearing potential practicing an acceptable method of birth control.

         15. Understanding of study procedures and willingness to comply for the entire length of
             the study and to give written informed consent

        Exclusion Criteria:

          1. Known hypersensitivity to the study drug or to any of its components

          2. CHF (NYHA = Class IV) or LVEF≤40%

          3. COPD &gt; Stage 3 (FEV1&lt;50%, FEV1/FVC&lt;70%);

          4. Cirrhosis (Child-Pugh Class C score);

          5. Serum Albumin level &lt; 3 g/dl

          6. Any other severe concurrent disease which in the judgment of the investigator would
             make the subject inappropriate for entry into this study

          7. History of human immunodeficiency virus (HIV) infection

          8. History of chronic active hepatitis including subjects who are carriers of hepatitis
             B virus (HBV) or hepatitis C virus (HCV).

          9. Presence of uncontrolled infection.

         10. Evidence of active bleeding or bleeding diathesis

         11. Brain metastases in symptomatic patients requiring ≥4 mg dexametasone/day. However,
             patients with treated brain metastases by surgery or radiation who are stable and
             symptom-free (&lt;4 mg dexametasone/day) for a minimum period of 4 weeks post-treatment
             are eligible.

         12. Pregnant or lactating

         13. Treatment with other investigational drugs within 14 days of start of the study drug
             for non-myelosuppressive agents, and within 28 days of start of the study drug for
             myelosuppressive agents.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alberto Gabizon, Prof.</last_name>
    <phone>+972 77 9055361</phone>
    <email>alberto.gabizon@lipomedix.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia Ohana, Dr.</last_name>
    <phone>+972-2- 5866177</phone>
    <email>patricia.ohana@lipomedix.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Tahover, MD</last_name>
      <phone>+972-50-7163123</phone>
      <email>esthert@hadassah.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Novatrials CRO Noga Brunicki</last_name>
      <phone>+972 52-4532325</phone>
      <email>noga@novatrials.com</email>
    </contact_backup>
    <investigator>
      <last_name>Esther Tahover, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raanan Berger, MD</last_name>
      <phone>+972-3-5307038</phone>
      <email>Raanan.Berger@sheba.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Novatrials CRO Noga Brunicki</last_name>
      <phone>+972 -52-4532325</phone>
      <email>noga@novatrials.com</email>
    </contact_backup>
    <investigator>
      <last_name>Raanan Berger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 21, 2013</lastchanged_date>
  <firstreceived_date>October 8, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>phase 1</keyword>
  <keyword>dose escalating</keyword>
  <keyword>prodrug</keyword>
  <keyword>mitomycin C</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
